Skip to main content
. 2021 Apr 1;16(4):e0248870. doi: 10.1371/journal.pone.0248870

Fig 4.

Fig 4

Enhanced susceptibility of A375P (left panels) and SK-MEL-28 (right panels) human melanoma cancer cells to (A) NK-92 and (B) primary NK cells by treatment with PD-L1 inhibitor or siRNA PD-L1 (light brown–control; light green–control siRNA; dark green–PD-L1 siRNA; dark brown–PD-L1 inhibitor, respectively.). The experiments were performed three times. (p < 0.05, *; p < 0.001, ***).